[A19-27] Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79

Last updated 02.05.2019

Project no.:

Commission awarded on 26.03.2019 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:
Airways and respiratory system


Maintenance treatment in adults with moderate to severe COPD who still have symptoms under a combination of a LABA and a LAMA

Result of dossier assessment:

Additional analysis of a comparison with a treatment that is not in line with the appropriate comparator therapy; assessment result of A18-79 unchanged


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2019-05-02 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form